Sanofi asks US court to halt diabetes drug patent fight with Mylan

In a stay application filed on Friday, Sanofi said a recent U.S. Court of Appeals for the Federal Circuit decision upholding the invalidation of two Lantus patents should be temporarily stopped from going into effect.

US: Pharmaceutical company Sanofi has asked the U.S. Supreme Court to halt its patent litigation with Mylan NV over the diabetes drug Lantus while the justices mull whether to weigh in on constitutional questions raised by the case.

Read also: Sanofi Completes Acquisition of Synthorx

In a stay application filed on Friday, Sanofi said a recent U.S. Court of Appeals for the Federal Circuit decision upholding the invalidation of two Lantus patents should be temporarily stopped from going into effect.

Read also: Sanofi being probed over birth defects related to Epilepsy drug Depakine